Does Interleukin 2 Still Have a Role in Cancer Immunotherapy? – The PROCLAIM[SM] Registry
LONDON, December 15, 2016 /PRNewswire/ —
Howard L Kaufman, Oncology & Hematology Review, 2016;12(2):77-9 DOI: https://doi.org/10.17925/OHR.2016.12.02.77
Published recently in Oncology & Hematology Review, the peer-reviewed journal from touchONCOLOGY, Howard L Kaufman discusses the continuing role of high dose interleukin (HD IL-2), an approved therapy for the treatment of metastatic renal cell carcinoma (mRCC) and metastatic melanoma (mM) that is capable of inducing durable complete responses. The role and clinical value of HD IL-2 needs to be re-examined and better delineated in this era of emerging targeted therapy and immune checkpoint blockade therapies. This editorial presents a perspective based on recent experience using PROCLAIM[SM], a large multicenter retrospective and prospective registry of patients receiving HD IL-2. The data confirms the potential for durable survival as first reported for HD IL-2 over two decades ago, and supports further investigation of IL-2 therapy in combination or sequence with immune checkpoint inhibitors.
The full peer-reviewed, open-access article is available here:
https://doi.org/10.17925/OHR.2016.12.02.77
Disclosure: Howard L Kaufman has served on advisory boards for Prometheus. This article is a short opinion piece and has not been submitted to external peer reviewers, but was reviewed by the Editorial Board before publication.
Note to the Editor
touchONCOLOGY (a division of Touch Medical Media) publishes
Oncology & Hematology Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of oncology and hematology. The aim of these reviews is to break down the high science from ‘data-rich’ primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
https://www.touchONCOLOGY.com
For inquires please contact:
Nicola Cartridge – Managing Editor
editor@touchmedicalmedia.com
T: +44-(0)207-193-3186
Providing practical opinion to support best practice for busy healthcare professionals.
LONDON, December 15, 2016 /PRNewswire/ —
Howard L Kaufman, Oncology & Hematology Review, 2016;12(2):77-9 DOI: https://doi.org/10.17925/OHR.2016.12.02.77
Published recently in Oncology & Hematology Review, the peer-reviewed journal from touchONCOLOGY, Howard L Kaufman discusses the continuing role of high dose interleukin (HD IL-2), an approved therapy for the treatment of metastatic renal cell carcinoma (mRCC) and metastatic melanoma (mM) that is capable of inducing durable complete responses. The role and clinical value of HD IL-2 needs to be re-examined and better delineated in this era of emerging targeted therapy and immune checkpoint blockade therapies. This editorial presents a perspective based on recent experience using PROCLAIM[SM], a large multicenter retrospective and prospective registry of patients receiving HD IL-2. The data confirms the potential for durable survival as first reported for HD IL-2 over two decades ago, and supports further investigation of IL-2 therapy in combination or sequence with immune checkpoint inhibitors.
The full peer-reviewed, open-access article is available here:
https://doi.org/10.17925/OHR.2016.12.02.77
Disclosure: Howard L Kaufman has served on advisory boards for Prometheus. This article is a short opinion piece and has not been submitted to external peer reviewers, but was reviewed by the Editorial Board before publication.
Note to the Editor
touchONCOLOGY (a division of Touch Medical Media) publishes
Oncology & Hematology Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of oncology and hematology. The aim of these reviews is to break down the high science from ‘data-rich’ primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
https://www.touchONCOLOGY.com
For inquires please contact:
Nicola Cartridge – Managing Editor
editor@touchmedicalmedia.com
T: +44-(0)207-193-3186
Providing practical opinion to support best practice for busy healthcare professionals.